Clinical Trials Browser

OTHER × Small Cell Lung Carcinoma × Nivolumab × Clear all

NCT03223155 2026-03-04

COSINR

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT03728361 2025-12-18

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Phase 2 Active not recruiting

EndocrineNETThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT03670056 2025-07-20

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT04165330 2025-02-24

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Phase 1/2 Active not recruiting

SarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Sarcoma, Small Cell Lung Carcinoma

NCT03043599 2024-12-20

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Phase 1/2 Completed

21 enrolled 11 charts

Small Cell Lung Carcinoma

NCT03958045 2024-10-22

Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma

Phase 2 Completed

33 enrolled 15 charts

Small Cell Lung Carcinoma

NCT02978404 2024-06-28

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Phase 2 Completed

CNSDermatologicGenitourinaryThoracic

Clear-cell metastatic renal cell carcinoma, Brain Neoplasms, Melanoma, Small Cell Lung Carcinoma

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Phase 1 Terminated

Small Cell Lung Carcinoma

NCT03083691 2024-01-17

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03662074 2023-08-02

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 14 charts

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03406715 2023-03-30

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Phase 2 Terminated

14 enrolled 12 charts

Lung Diseases, Lung Neoplasms, Small Cell Lung Carcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04173325 2022-06-14

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Phase 1 Terminated

Lung Neoplasms, Small Cell Lung Carcinoma